The Activation of Brown and Beige Fat and Role in Insulin Sensitivity

Trial Profile

The Activation of Brown and Beige Fat and Role in Insulin Sensitivity

Recruiting
Phase of Trial: Phase 0

Latest Information Update: 03 Jun 2017

At a glance

  • Drugs Mirabegron (Primary) ; Pioglitazone (Primary)
  • Indications Metabolic syndrome; Obesity
  • Focus Biomarker; Pharmacodynamics
  • Most Recent Events

    • 24 May 2017 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.
    • 24 May 2017 Status changed from not yet recruiting to recruiting.
    • 05 Oct 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top